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Abstract
Background The pharmacokinetic properties of liraglutide, a
glucagon-like peptide-1 receptor agonist approved for the
treatment of type 2 diabetes mellitus (T2D), have been estab-
lished in healthy individuals and subjectswithT2D.Liraglutide
has been under investigation as adjunct treatment to insulin in
type 1 diabetes mellitus (T1D). This single-center, double-
blind, placebo-controlled, crossover, clinical pharmacology
trial is the first to analyze the pharmacokinetic properties of
liraglutide as add-on to insulin in T1D.
Methods Subjects (18–64 years; body mass index
20.0–28.0 kg/m2; glycated hemoglobin B9.5 %) were
randomized 1:1:1 to 0.6, 1.2, or 1.8 mg liraglutide/placebo.
Each group underwent two 4-week treatment periods (li-
raglutide then placebo or placebo then liraglutide) sepa-
rated by a 2- to 3-week washout. Both trial drugs were
administered subcutaneously, once daily, as adjunct to
insulin. A stepwise hypoglycemic clamp was performed at
the end of each treatment period (data reported previously).
Pharmacokinetic endpoints were derived from liraglutide
concentration–time curves after the final dose and exposure
was compared with data from previous trials in healthy
volunteers and subjects with T2D.
Results The pharmacokinetic properties of liraglutide in
T1D were comparable with those observed in healthy
volunteers and subjects with T2D. Area under the steady-
state concentration–time curve (AUC) and maximum
plasma concentration data were consistent with dose pro-
portionality of liraglutide. Comparison of dose-normalized
liraglutide AUC suggested that exposure in T1D, when
administered with insulin, is comparable with that observed
in T2D.
Conclusions Liraglutide, administered as adjunct to insulin
in subjects with T1D, shows comparable pharmacokinetics
to those in subjects with T2D.
ClinicalTrials.gov Identifier: NCT01536665.
Key Points
This is the first trial to describe the pharmacokinetic
properties of liraglutide as adjunct treatment to
insulin in type 1 diabetes mellitus (T1D).
Based on data obtained at steady-state,
pharmacokinetic properties were comparable with
those previously observed in healthy volunteers and
subjects with type 2 diabetes mellitus.
Pharmacokinetic endpoints derived from liraglutide
concentration–time curves after the last dose were
consistent with dose proportionality.
These results add to the clinical profile of liraglutide
in T1D. The efficacy and safety of liraglutide as
adjunct therapy to insulin in this population have
also been evaluated in three phase III trials (http://
www.clinicaltrials.gov; NCT02098395,
NCT01836523, NCT02092896) and one phase IV
trial (NCT01612468).
& Thomas R. Pieber
thomas.pieber@medunigraz.at
1 Division of Endocrinology and Diabetology, Medical
University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
2 Division of Medicine and Science, Novo Nordisk A/S,
Søborg, Denmark
3 Academic Unit of Diabetes, Endocrinology and Metabolism,
University of Sheffield, Sheffield, UK
Clin Pharmacokinet
DOI 10.1007/s40262-016-0413-4
1 Introduction
The glucagon-like peptide-1 (GLP-1) receptor agonists
(GLP-1 RAs) have multiple physiologic effects, including
glucose-dependent stimulation of insulin secretion from the
pancreas and reduction of glucagon secretion [1]. They are
also associated with weight loss and reductions in systolic
blood pressure [1], in conjunction with a minor increase in
heart rate of 1–2 beats/min [2]. Positive results in phase III
clinical trials have made them a well-established thera-
peutic class in type 2 diabetes mellitus (T2D).
GLP-1 RAs have shown potential in the treatment of
type 1 diabetes mellitus (T1D) in preclinical and clinical
studies [3–7], and their glucose-dependent mode of action
[8] leads to low risk of hypoglycemia and may reduce
excessive postprandial glucagon secretion (allowing sub-
jects to reduce their total daily insulin dose). Among these
GLP-1 RAs is liraglutide, a once-daily human GLP-1 RA
that has 97 % homology to native GLP-1 and is already
widely used for the treatment of T2D [9, 10].
Liraglutide, in combination with insulin, has demon-
strated potential benefits to glycemic control in several
small studies in subjects with T1D [4, 5, 11, 12], including
reduced frequency and amplitude of fasting and postpran-
dial hyperglycemic excursions (believed to be due to
inhibition of postprandial hyperglucagonemia), decreased
incidence of hypoglycemia, decreased insulin requirement,
reductions in systolic blood pressure, and weight loss.
The pharmacokinetics of liraglutide have been established
in several populations, including healthy volunteers of different
ethnicities [13–17], non-diabetic individuals with varying
degrees of hepatic [18] or renal [19] impairment, and adults
[10, 20, 21] and children [22] with T2D. Understanding the
pharmacokinetic properties of liraglutide in subjects with T1D
is important in establishing its clinical profile in this population.
In a recent, randomized, controlled clinical pharmacology
trial, liraglutide preserved the counter-regulatory response to
hypoglycemia, decreased subjects’ insulin requirements, and
was associated with reduced body weight relative to placebo
in subjects with T1D [7]. Liraglutide was well tolerated and
safety observations were in line with those observed previ-
ously in subjects with T2D. The present article, based on
analysis of subjects enrolled in this clinical pharmacology
trial, is the first to describe the pharmacokinetic properties of
liraglutide as adjunct therapy to insulin in T1D.
2 Materials and Methods
2.1 Participants
The trial included male and female subjects aged
18–64 years (inclusive) with a clinical diagnosis of T1D
for C12 months. All participants had been treated with
multiple daily insulin injections or continuous subcuta-
neous insulin infusion for C12 months. Subjects also had a
body mass index of 20.0–28.0 kg/m2 (inclusive), body
weight C52 kg, and glycated hemoglobin (HbA1c) B9.5 %.
Key exclusion criteria included the use of liraglutide or
exenatide within 3 months before randomization, recurrent
severe hypoglycemia (more than one episode within the
past 12 months), hypoglycemia unawareness, or severe
autonomic neuropathy.
2.2 Trial Design
The design of the main trial, including confirmation of the
ethical conduct and approval of the trial, has been previ-
ously reported in full [7]. Briefly, it was a randomized,
single-center, double-blind, placebo-controlled, crossover
trial in three parallel groups of subjects with T1D. Subjects
were randomized 1:1:1 to one of three liraglutide dose
groups (0.6, 1.2, or 1.8 mg), and placebo in equivalent
volume, administered once daily in the evening by sub-
cutaneous injection, as adjunct to insulin.
Each group underwent two 4-week treatment periods
(half liraglutide then placebo and half placebo then
liraglutide) separated by a 2- to 3-week washout period
before crossover. Liraglutide was initiated at 0.6 mg/day,
irrespective of the dose group to which the subject had
been randomized, followed by weekly dose escalations of
0.6 mg until the target dose of 0.6, 1.2, or 1.8 mg was
reached.
At the end of each treatment period, a stepwise hypo-
glycemic clamp was performed. The design and results of
the clamp were reported by Pieber et al. [7]. The final dose
of trial product was given in the evening, at 22:00 h on the
day before the clamp, and serial sampling for plasma
concentration of liraglutide was initiated at that timepoint
and continued for 60 h post-dose. In this publication, only
the pharmacokinetic data for the liraglutide dosing period
are reported.
2.3 Pharmacokinetic Assessments and Statistical
Analysis
The current article summarizes pharmacokinetic endpoints
derived from the steady-state concentration–time curves
for liraglutide 0.6, 1.2, and 1.8 mg, including area under
the curve (AUC), maximum serum concentration (Cmax),
time to Cmax (tmax), terminal half-life (t), clearance (CL/
F), volume of distribution (Vz/F), and the minimum
liraglutide concentration in a dosing interval (Ctrough;
measured just before the final dose). Blood samples for
assessment of these pharmacokinetic endpoints were drawn
at steady-state immediately prior to, and nominally at 2, 5,
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8, 10, 12, 14, 16, 20, 24, 36, 48, and 60 h after, adminis-
tration of the final dose.
Liraglutide was analyzed in plasma using a specific
enzyme-linked immunosorbent assay (ELISA) that
employed two monoclonal antibodies directed against dif-
ferent liraglutide epitopes [13]. The two antibodies used for
this sandwich assay were directed against the N- and
C-terminal region of the liraglutide molecule. The cali-
bration range of the assay was 20–2000 pmol/L, with a
lower limit of quantification (LLOQ) of 30 pmol/L and an
upper limit of quantification (ULOQ) of 2000 pmol/L. An
additional calibration anchor point at 20 pmol/L was
included to assist the curve-fitting process and was not
subjected to any acceptance criteria.
Dose-normalized liraglutide AUCs from this trial were
compared against those from three trials of liraglutide in
subjects with T2D [20, 23, 24]. Two of these were clinical
pharmacology studies [20, 23], selected because they
included steady-state liraglutide pharmacokinetic profiles.
The third trial was a phase III trial [25] of liraglutide
monotherapy, including pharmacokinetic data used for
population pharmacokinetic analysis [24].
Pharmacokinetic endpoints were determined using non-
compartmental methods. Actual time since the start of final
dose administration was used for all endpoints.
AUC was approximated using the trapezoidal rule on
the observed concentrations. Cmax for each liraglutide
dose was derived as the maximum of all valid concen-
trations, and tmax was then determined as the corre-
sponding time point to Cmax. The terminal elimination
rate constant (kz) was estimated by log-linear regression
on the terminal part of the concentration–time curve, and
t was then calculated as t = ln2/kz. CL/F was calcu-
lated as CL/F = dose/AUC0–24 h. Vz/F was estimated as
Vz/F = (CL/F)/kz.
All pharmacokinetic endpoints were summarized by
treatment using descriptive statistics. Post hoc statistical
analysis of dose proportionality of selected endpoints was
conducted using a linear model of log (AUC0–24 h) and log
(Cmax) with logarithmic-transformed dose as the covariate.
According to the model, doubling the dose resulted in an
increase in the endpoint with a factor of 2b, where b is the
slope of the linear regression, i.e. b = 1 corresponds to
perfect dose proportionality
3 Results
3.1 Demographics
Pharmacokinetic profiles were available for 40/45 subjects
enrolled in the trial (liraglutide 0.6 mg, n = 14; 1.2 mg,
n = 13; 1.8 mg, n = 13) [7].
Demographics and baseline characteristics were similar
across the three dose groups analyzed (Table 1). All subjects
were White, and the majority (65 %) were male. Across the
three dose groups, mean age ranged from 32.4 to 38.1 years,
mean body weight from 72.3 to 75.2 kg, and mean duration of
diabetes from 15.4 to 18.6 years. Serum creatinine was
\126 lmol/L (male) or\111 lmol/L (female) in all groups.
Mean fasting C-peptide levels were very low, as expected in an
exclusively T1D population; a total of eight subjects (three in
each of the 0.6 and 1.2 mg dose groups; two in the 1.8 mg dose
group) were C-peptide-positive (C0.06 nmol/L).
3.2 Pharmacokinetics
Pharmacokinetic profiles for all three liraglutide doses are
presented in Fig. 1. Median tmax and geometric mean t
were comparable between the three dose groups (Table 2).
Median tmax values ranged from 8 to 10 h (10 h for the
entire trial population), while geometric mean t values
ranged from 15.3 to 18.8 h (16.7 h for the entire popula-
tion). CL/F and Vz/F were also comparable between dose
groups, with geometric mean values of 0.85 L/h and
27.4 L, respectively, across the trial population (Table 2).
Plots of steady-state AUC and Cmax versus dose (post
hoc analysis) were consistent with dose proportionality
Table 1 Participant demographics and baseline characteristics
Liraglutide
0.6 mg
[n = 14]
Liraglutide
1.2 mg
[n = 13]
Liraglutide
1.8 mg
[n = 13]
Liraglutide
All doses
[n = 40]
Males/females [n (%)] 8 (57)/6 (43) 10 (77)/3(23) 8 (62)/5 (38) 26 (65)/14 (35)
Age, years [range] 38.1 (11.2) [20.0–55.0] 34.3 (12.9) [20.0–55.0] 32.4 (8.8) [18.0–45.0] 35.0 (11.1) [18.0–55.0]
Body weight, kg [range] 75.2 (14.4) [55.7–91.4] 72.3 (9.6) [57.5–86.1] 74.6 (10.4) [60.0–89.8] 74.1 (11.5) [55.7–91.4]
BMI, kg/m2 [range] 24.0 (2.7) [20.2–28.2] 23.1 (2.1) [20.2–26.2] 24.5 (2.4) [20.5–28.0] 23.9 (2.4) [20.2–28.2]
Duration of diabetes, years [range] 18.5 (8.9) [6.4–33.9] 18.6 (10.7) [6.7–43.8] 15.4 (9.1) [1.9–33.7] 17.5 (9.5) [1.9–43.8]
Serum creatinine, lmol/L [range] 74.8 (14.2) [52.0–97.0] 85.2 (20.0) [54.0–117.0] 74.5 (8.7) [58.0–92.0] 78.1 (15.5) [52.0–117.0]
Data are mean (SD) unless otherwise stated
BMI body mass index, SD standard deviation, SD standard deviation
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(Fig. 2): estimated 2b for AUC0–24 h and Cmax (95 % CI)
were 2.06 (1.83–2.33) and 2.10 (1.86–2.37), respectively.
The finding of dose proportionality was supported by the
liraglutide Ctrough for the three dose groups (concentration
value at time zero on the concentration–time profile)
(Fig. 1).
Visual comparison of dose-normalized liraglutide AUC
for subjects with T1D in this trial, alongside results from
two clinical pharmacology studies in subjects with T2D
(n = 12, Hermansen et al. [20]; and n = 32, Morrow et al.
[23]), and one population pharmacokinetic analysis in T2D
(458 subjects who received liraglutide 1.2 or 1.8 mg, Ing-
wersen et al. [24]), suggested that liraglutide exposure
largely overlaps in subjects with T1D and T2D (Fig. 3).
However, differences in the aforementioned studies in
demographic characteristics such as body weight (mean,
kg: 98.2 [23], 88.2 [20], 93.1 [24], and 74.1 in the current
study) and sex distribution (male:female ratio: 2.3 [23], 1.2
[20], 0.9 [24], and 1.9 in the current study) should be taken
into account when interpreting these findings.
4 Discussion
This analysis of steady-state pharmacokinetic data in sub-
jects with T1D receiving liraglutide 0.6, 1.2, or 1.8 mg as
adjunct to insulin indicates similar pharmacokinetic prop-
erties in individuals with T1D and T2D. The minor dif-
ferences identified between these populations were slightly
higher Vz/F (27.4 vs.11–17 L) and longer plasma half-life
(16.7 vs. 13 h) in individuals with T1D than previously
reported in healthy volunteers and individuals with T2D
[26, 27]; methodological differences between studies (e.g.
differences in trial eligibility criteria, background medica-
tions, blood sampling times) may also have contributed to
these differences. The analysis also demonstrates that
liraglutide is consistent with dose-proportional pharma-
cokinetics in T1D, which aligns with results from studies in
healthy volunteers and in adults and adolescents with T2D,
including both White and Asian populations
[13, 14, 16, 17, 21, 22]. Based on dose-normalized AUC
values, exposure appeared to largely overlap between
liraglutide-treated subjects with T1D in the current trial and
subjects with T2D receiving liraglutide 1.8 mg in two
clinical pharmacology studies and one population phar-
macokinetic study [20, 23, 24], although baseline demo-
graphic and clinical characteristics were different across
the studies compared in this analysis and will have had an
impact on the pharmacokinetic data obtained (e.g. there
was a larger proportion of heavier male subjects in the
study by Morrow et al. than the study by Hermansen et al.,
leading to reduced exposure in the former). Covariate
Fig. 1 Liraglutide concentration profiles in patients with type 1
diabetes. Green curve represents liraglutide 0.6 mg; blue curve
represents liraglutide 1.2 mg; orange curve represents liraglutide
1.8 mg. Data are geometric mean with 95 % confidence intervals
Table 2 Pharmacokinetic
parameters from a non-
compartmental analysis
Liraglutide
0.6 mg
[n = 14]
Liraglutide
1.2 mg
[n = 13]
Liraglutide
1.8 mg
[n = 13]
Liraglutide
All doses
[n = 40]
AUC0–24 h, pmol h/L 181,464 (33) 384,151 (20) 569,771 (26) –
Cmax, pmol/L 9257 (33) 20,067 (18) 29,751 (28) –
Ctrough, pmol/L 5209 (43) 13,051 (20) 18,287 (32) –
tmax, h 9 8 10 10
t, h 15.3 (15.6) 16.4 (135.2) 18.8 (144.1) 16.7 (128.8)
CL/F, L/h 0.88 (28.4) 0.83 (18.2) 0.84 (23.4) 0.85 (23.6)
Vz/F, L 27.0 (36.2) 26.0 (88.1) 29.3 (120.2) 27.4 (95.4)
Data are geometric mean (CV, %), with the exception of tmax, which is median. Overall liraglutide data (all
doses) are included for dose-independent parameters
AUC0–24 h area under the curve from time zero to 24 h, Cmax maximum concentration, CL/F clearance,
Ctrough trough concentration, CV coefficient of variation, t terminal half-life, tmax time to Cmax, Vz/F
volume of distribution
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analysis was not carried out in the current study due to
small sample size.
Overall, pharmacokinetic parameters in subjects with
T1D in the current trial were comparable with those in
healthy volunteers and subjects with T2D in previous
studies [13, 14, 16–20, 26]. In particular, median tmax
(10 h) was within the range of 8–12 h observed in studies
with healthy volunteers and subjects with T2D, as was
geometric mean CL/F (0.85 L/h in the current trial; 1.2 L/h
in studies with healthy volunteers and subjects with T2D)
[26]. Geometric mean t was 16.7 h, which is above the
approximately 13 h observed in previous studies [26],
while geometric mean Vz/F in the current analysis (27.4 L)
was also slightly higher than values in previous studies in
healthy volunteers and subjects with T2D (11–17 L) [26].
These differences may possibly reflect different half-lives
in types 1 and 2 diabetes, driven by differences in
Vz/F. Despite these minor differences, and notwithstanding
possible differences in baseline demographics, liraglutide
exposure (in terms of AUC) largely overlapped, and
therefore appeared comparable, in T1D and T2D. This
finding is in accordance with the similar clearance values in
these populations. Establishing that the pharmacokinetic
profile of liraglutide in T1D is consistent with that
observed in healthy subjects and in T2D was also an
important step in clinical development. Five recently
completed studies, two conducted by Novo Nordisk
(NCT02098395, NCT01836523) and three investigator-
initiated trials [28–30] examined the efficacy and safety of
liraglutide as adjunct therapy to insulin in the treatment of
T1D to further clarify the clinical picture.
This trial is the first to present information on the
pharmacokinetic properties of liraglutide as adjunct ther-
apy to insulin in subjects with T1D, including across three
different liraglutide doses; however, there are some limi-
tations to the current work. First, all subjects were Cau-
casian and further work will be required to assess the
pharmacokinetic properties of liraglutide in non-White
populations with T1D and how these compare with T2D.
Second, although allocation to active or placebo treatment
was blinded, the dose level was not; however, this is
unlikely to have affected the pharmacokinetic outcomes
given that participants would not have been able to influ-
ence these outcomes based on knowledge of the random-
ization group. Third, although the results are consistent
with dose proportionality of liraglutide in T1D, this trial
was not specifically designed to address this, and the
analysis was performed post hoc. Finally, the trial was
Fig. 2 Liraglutide a AUC and b Cmax according to dose in patients
with type 1 diabetes. Solid lines represent the estimated curves based
on a linear model with logarithmic transformed dose as covariate
fitted to the logarithmic transformed endpoint under the assumption of
dose proportionality (i.e. an exponent of 1 in the regression model).
Symbols represent observed values. AUC area under the curve, Cmax
maximum concentration
Fig. 3 Scatter plot of dose-normalized liraglutide AUC for patients
with type 1 diabetes taking insulin compared with patients with type 2
diabetes. Horizontal lines represent the geometric mean of the group.
Data from the three trials in type 2 diabetes are also dose-normalized.
Differences in baselines demographics, particularly sex and body
weight, as described in the text, may have influenced outcomes. AUC
steady-state area under the curve, PK pharmacokinetics
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performed in subjects with T1D only, meaning that the
comparison to pharmacokinetics in subjects with T2D was
made using historical data.
5 Conclusions
On the basis of results from this trial, we conclude that
when liraglutide is administered as adjunct therapy to
insulin in subjects with T1D, liraglutide exposure is dose-
proportional and overlaps with that in subjects with T2D,
and its pharmacokinetic properties are comparable with
those in healthy volunteers and subjects with T2D.
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